





MEDUWA-Vecht(e) Project 2017-2020

MEDizin Unerwünscht im WAsser / MEDicines Unwanted in WAter / MEDicijnen Uit het WAter

HCWH Workshop, November 12 2019, Brussels, Belgium



By Alfons Uijtewaal & Margarita Amador

Stichting Huize Aarde

Websites: <u>huizeaarde.nl</u> & <u>groenegezondheid.nl</u>

E-mail: post@huizeaarde.nl

Telephone: +316 432 89 163



inter-sectoral cross-border MEDUWA-Vecht(e) coalition















































Radboud Universiteit











budget € 8.5 million co-funders:













Ministerium für Wirtschaft, Innovation, Digitalisierung und Energie des Landes Nordrhein-Westfalen











environmental cycle of pharmaceuticals & antimicrobial resistance



human exposure to medicines and antimicrobial resistance via food, water and air






Legend:

dark red = accumulation light red = bioaccumulation and/or biomagnification





carbamazepine in urine of healthy people












carbamazepine in urine of healthy people












increase in azole resistant fungi in plants and humans










environmental medicines: endocrine disruptors?

non-hormonal medicines with ED-effect

medicine group	sub group	examples	number studies
analgesics	NSAID	ibuprofen acetaminophen	11
antidepressants	SSRI	fluoxetin sertralin	10
anti-fungal agents	azoles	ketoconazole clotrimazole	7
cholesterol reducers	fibrates	bezafibrate clofibrate	5
antihypertensives	beta-blockers	salbutamol propanolol	4
anti-cancer agents	anti-estrogenics	tamoxifen	2
antihypertensives	diuretics	furosemide	2
antibacterial agents	antibiotics	amoxicillin erythromycin	1
antiepileptics	Na-blocker	carbamazepin	1
antiacids	H2-blocker	cimetidine	1










societal consequences of medicinal environmental cycle




sustainability of measures

by human health sector by veterinary health sector fermentation or combustion of manure; advanced drinking water treatment oxidation of urine collection of excess medicines advanced central sewage treatmentbiological degradation advanced decentralized in manure sewage treatment intelligent fertilization separating waste streams at source authorisation on the basis of an environmental impact assessment greening of molecules non-chemical diagnosis & treatment vaccination non-chemical diagnosis and treatment promotion of animal health health promotion reduced meat consumption; reduction of food waste One Health



Ecosystems

organogram of the MEDUWA-Vecht(e) Project



Europäische Union

Europese Unie

MEDUWA


intervention classes of MEDUWA

WP	product	prevention	mitigation	monitoring	visualisation communication
1.1	Watershed info system				
1.2	Gray water footprint				
1.3	Risk assessment				
2.1	Automatic in-situ monitoring				
2.2	Wireless water monitoring				
2.3	Nanofiltration				
3	PAW oxidation				
4.1	Phytoremediation				
4.2	Herbal antibiotic replacement				
4.3	Algal antibibiotic replacement				
5	Wireless cattle monitoring				
6	Biopharmaceuticals				















biopharmaceutical: alkaline phosphatase (AP)

- Production and application of AP as a natural anti-inflammatory medicine.
- In humans: eg. to prevent steroid use against inflammations in artritis, cystic fibrosis and during cardiac operations.
- In animals: to replace persistent chemicals against mastitis, colitis, weaning diarrhea.










MEDUWA-innovations



plant and algae mixtures instead of antibiotics



To:

- replace antibiotics in animals and humans
- promote health and growth;
- prevent the contamination of soil, air and water with medicines;
- prevent the development of resistances;
- remediate contaminated water and soil (phytoremediation)











MEDUWA-innovations



plant

species

plant and algae mixtures instead of antibiotics

bacterial species

Bacillus subtilis	S. aureus	E. coli	Ps. aeruginosa
1:20 - 1:2560	1:20 - 1:2560	1:20 - 1:2560	1:20
n.e.	n.e.	n.e.	n.e.
n.e.	1:20 – 1:40	n.e.	n.e.
1:20 - 1:2560	1:20 - 1:2560	1:20 - 1:2560	n.e.
1:20 - 1:2560	1:20 – 1:2560	1:20 - 1:2560	1:20 - 1:40
1:20 - 1:2560	1:20 - 1:2560	1:20 - 1:2560	1:20 - 1:40
n.e.	n.e.	n.e.	n.e.
1:20	1:20	n.e.	n.e.
n.e.	n.e.	n.e.	n.e.
1:20 - 1:40	1:20	1:20	n.e.
n.e.	n.e.	n.e.	n.e.
n.e.	1:20	n.e.	n.e.
1:20 - 1:2560	1:20 – 1:1280	1:20 – 1:640	n.e.
n.e.	n.e.	n.e.	n.e.
1:20 - 1:2560	1:20 - 1:1280	1:20 – 1:1280	1:20
1:20 - 1:2560	1:20 - 1:1280	1:20 - 1:1280	1:20
1:20 - 1:160	1:20 – 1:160	n.e.	n.e.
n.e.	n.e.	n.e.	n.e.
1:20 - 1:2560	1:20 - 1:2560	1:20 - 1:1280	1:20
1:20 - 1:2560	1:20 - 1:1280	1:20 – 1:640	n.e.
1:20 - 1:2560	1:20 - 1:2560	1:20 - 1:2560	1:20
1:20 - 1:2560	1:20 - 1:2560	1:20 - 1:2560	1:20
n.e.	n.e.	n.e.	n.e.
1:20 - 1:2560	1:20 – 1:640	1:20 - 1:320	n.e.
1:20 - 1:2560	1:20 - 1:1280	1:20 - 1:640	n.e.
1:20	1:20	n.e.	n.e.
1:20 – 1:40	1:20 – 1:40	1:20	n.e.
1:20 - 1:2560	1:20 – 1:1280	1:20 – 1:640	1:20
1:20 – 1:40	1:20 - 1:80	n.e.	1:20
1:20 – 1:80	1:20 - 1:80	n.e.	1:20 - 1:40
n.e.	n.e.	n.e.	n.e.
1:20-1:256	1:20 – 1:256	1:20 - 1:2650	1:20 - 1:40

Intermediate results:

- 15 species and mixtures tested
- Effects differ between bacteria
- Some herbs kill bacteria (green)
- Some only inhibit growth (yellow)













green medicines: utopia or option

examples of biodegradable medicines (according to OECD tests)

isosorbide dinitrate	> 90%
mesalazine	> 90%
penicillin V	> 90%
piracetam	> 90%
cytarabine	> 90%
acetylsalicylic acid	81%
valproic acid	78%
glufosfamide	72%

Kümmerer K. in Kümmerer K. and M. Hempel (Eds.), 2010, Green and Sustainable Pharmacy, Springer.



Prof. Klaus Kümmerer

- Stability does not exclude biodegradability.
- Biodegradability can be included intentionally.
- Biodegradability can improve therapeutic effect and reduce side effects.







benign-by-design-medicines

not biodegradable

biodegradable









green medicines: phytotherapeutics

International Journal of Neuropsychopharmacology, Page 1 of 11. © CINP 2014 doi:10.1017/S1461145714000017

Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized double-blind comparison to placebo and paroxetine

Siegfried Kasper¹, Markus Gastpar², Walter E Müller³, Hans-Peter Volz⁴, Hans-Jürgen Möller⁵, Sandra Schläfke⁶ and Angelika Dienel⁶







¹ Department of Psychiatry and Psychotherapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria

² Fliedner Klinik Berlin, Charlottenstraße 65, 10117 Berlin, Germany

³ Department of Pharmacology, Biocenter Goethe-University, Max-von-Laue-Straße 9, 60438 Frankfurt, Germany

⁴ Hospital for Psychiatry, Psychotherapy and Psychosomatic Medicine, Schloss Werneck, Balthasar-Neumann-Platz 1, 97440 Werneck, Germany

⁵ Clinic for Psychiatry and Psychotherapy, Ludwig Maximilians University, Nußbaumstraße 7, Munich, Germany

⁶ Dr. Willmar Schwabe GmbH & Co. KG, Willmar-Schwabe-Straße 4, 76227 Karlsruhe, Germany

priorities for action



- Stimulate cross-sectoral pilot projects that work on the whole life cycle of medicines.
- Develop & test source oriented solutions, including prevention.
- Incentives for start-ups and universities for research in biodegradable medicines.







